Načítá se...
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Over the past couple of decades, antibody–drug conjugates (ADCs) have revolutionized the field of cancer chemotherapy. Unlike conventional treatments that damage healthy tissues upon dose escalation, ADCs utilize monoclonal antibodies (mAbs) to specifically bind tumour-associated target antigens and...
Uloženo v:
| Vydáno v: | Biosci Rep |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Portland Press Ltd.
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4613712/ https://ncbi.nlm.nih.gov/pubmed/26182432 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BSR20150089 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|